Phathom Pharmaceuticals (PHAT) reported preliminary Q4 revenue late Wednesday of $57 million to $58 million.
Analysts polled by FactSet expect $56.2 million.
The company said it expects to achieve operating profitability in H2.
The company's shares fell 12% in after-hours trading. Phathom also announced a proposed public stock offering.